Inhibition	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
by	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
.	O

The	O
KBF1	B-protein
factor	I-protein
,	O
which	O
binds	O
to	O
the	O
enhancer	B-DNA
A	I-DNA
located	O
in	O
the	O
promoter	B-DNA
of	O
the	O
mouse	B-DNA
MHC	I-DNA
class	I-DNA
I	I-DNA
gene	I-DNA
H-2Kb	B-DNA
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1/p50	B-protein
factor	I-protein
binds	O
as	O
a	O
homodimer	B-protein
but	O
can	O
also	O
form	O
heterodimers	B-protein
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-DNA
and	I-DNA
v-rel	I-DNA
(	I-DNA
proto	I-DNA
)	I-DNA
oncogenes	I-DNA
.	O

The	O
dimerization	B-protein
domain	I-protein
of	O
KBF1/p50	B-protein
is	O
contained	O
between	B-protein
amino	I-protein
acids	I-protein
201	I-protein
and	I-protein
367	I-protein
.	O

A	O
mutant	O
of	O
KBF1/p50	B-protein
(	O
delta	B-protein
SP	I-protein
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	B-protein
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild-type	B-protein
proteins	I-protein
of	O
the	O
same	O
family	O
(	O
KBF1/p50	B-protein
,	O
c-	B-protein
and	I-protein
v-rel	I-protein
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans-acting	B-protein
dominant	I-protein
negative	I-protein
regulator	I-protein
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
which	O
contains	O
two	O
potential	O
NF-kappa	B-protein
B	I-protein
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co-transfected	O
into	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
the	O
delta	B-protein
SP	I-protein
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	B-protein
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	B-DNA
class	I-DNA
I	I-DNA
H-2Kb	I-DNA
promoter	I-DNA
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	B-cell_line
lines	I-cell_line
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.10	NULL
no.7	NULL
pp.1827-	NULL
1832	NULL
,	NULL
1991	NULL
Inhibition	NULL
of	NULL
transcription	NULL
factors	NULL
belonging	NULL
to	NULL
the	NULL
rel/NF-xB	NULL
family	NULL
by	NULL
a	NULL
transdominant	NULL
negative	NULL
mutant	NULL
Frédérique	NULL
Logeat	NULL
,	NULL
Nicole	NULL
Israél	NULL
'	NULL
,	NULL
Rosa	NULL
Ten	NULL
,	NULL
Volker	NULL
Blank	NULL
,	NULL
Odile	NULL
Le	NULL
Bail	NULL
,	NULL
Philippe	NULL
Kouriisky	NULL
and	NULL
Alain	NULL
Israél	NULL
Unité	NULL
de	NULL
Biologie	NULL
Moléculaire	NULL
du	NULL
Géne	NULL
,	NULL
U.277	NULL
Inserm-U.A	NULL
.	NULL

535	NULL
CNRS	NULL
and	NULL
'Laboratoire	NULL
d'Immunologie	NULL
Virale	NULL
,	NULL
Institut	NULL
Pasteur	NULL
,	NULL
25	NULL
Rue	NULL
du	NULL
Dr	NULL
Roux	NULL
,	NULL
75724	NULL
Paris	NULL
Cédex	NULL
15	NULL
,	NULL
France	NULL
Communicated	NULL
by	NULL
P.Kourilsky	NULL
The	NULL
KBF1	NULL
factor	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
enhancer	NULL
A	NULL
located	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
mouse	NULL
MHC	NULL
class	NULL
I	NULL
gene	NULL
H-2K	NULL
``	NULL
,	NULL
is	NULL
indistinguishable	NULL
from	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-xB	NULL
,	NULL
which	NULL
regulates	NULL
a	NULL
series	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
.	NULL

The	NULL
KBF1/p50	NULL
factor	NULL
binds	NULL
as	NULL
a	NULL
homodimer	NULL
but	NULL
can	NULL
also	NULL
form	NULL
heterodimers	NULL
with	NULL
the	NULL
products	NULL
of	NULL
other	NULL
members	NULL
of	NULL
the	NULL
same	NULL
family	NULL
,	NULL
like	NULL
the	NULL
c-re/	NULL
and	NULL
v-re/	NULL
(	NULL
proto	NULL
)	NULL
oncogenes	NULL
.	NULL

The	NULL
dimerization	NULL
domain	NULL
of	NULL
KBF1/pS50	NULL
is	NULL
contained	NULL
between	NULL
amino	NULL
acids	NULL
201	NULL
and	NULL
367	NULL
.	NULL

A	NULL
mutant	NULL
of	NULL
KBF1/p50	NULL
(	NULL
ASP	NULL
)	NULL
,	NULL
unable	NULL
to	NULL
bind	NULL
to	NULL
DNA	NULL
but	NULL
able	NULL
to	NULL
form	NULL
homo-	NULL
or	NULL
heterodimers	NULL
,	NULL
has	NULL
been	NULL
constructed	NULL
.	NULL

This	NULL
protein	NULL
reduces	NULL
or	NULL
abolishes	NULL
in	NULL
vitro	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
wild-type	NULL
proteins	NULL
of	NULL
the	NULL
same	NULL
family	NULL
(	NULL
KBF1/p50	NULL
,	NULL
c-	NULL
and	NULL
v-rel	NULL
)	NULL
.	NULL

This	NULL
mutant	NULL
also	NULL
functions	NULL
in	NULL
vivo	NULL
as	NULL
a	NULL
trans-acting	NULL
dominant	NULL
negative	NULL
regulator	NULL
:	NULL
the	NULL
transcriptional	NULL
inducibility	NULL
of	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
which	NULL
contains	NULL
two	NULL
potential	NULL
NF-xB	NULL
binding	NULL
sites	NULL
)	NULL
by	NULL
phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
)	NULL
is	NULL
inhibited	NULL
when	NULL
it	NULL
is	NULL
co-transfected	NULL
into	NULL
CD4*	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
ASP	NULL
mutant	NULL
.	NULL

Similarly	NULL
the	NULL
basal	NULL
as	NULL
well	NULL
as	NULL
TNF	NULL
or	NULL
IL1-induced	NULL
activity	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
H-2K	NULL
``	NULL
promoter	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
this	NULL
mutant	NULL
in	NULL
two	NULL
different	NULL
cell	NULL
lines	NULL
.	NULL

These	NULL
results	NULL
constitute	NULL
the	NULL
first	NULL
formal	NULL
demonstration	NULL
that	NULL
these	NULL
genes	NULL
are	NULL
regulated	NULL
by	NULL
members	NULL
of	NULL
the	NULL
rel/NF-xB	NULL
family	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
heterodimer/KBF1/rel/NF-xB/transdominant	NULL
negative	NULL
mutant	NULL
Introduction	NULL
Nuclear	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
H-2K	NULL
``	NULL
°	NULL
mouse	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
Kimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Baldwin	NULL
and	NULL
Sharp	NULL
,	NULL
1987	NULL
;	NULL
Isracl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Burke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

A	NULL
factor	NULL
called	NULL
KBFI	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
enhancer	NULL
A	NULL
sequence	NULL
(	NULL
Kimura	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
basal	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
genes	NULL
(	NULL
Israél	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

This	NULL
protein	NULL
was	NULL
purified	NULL
(	NULL
Yano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
and	NULL
the	NULL
cDNA	NULL
coding	NULL
for	NULL
KBFI	NULL
has	NULL
been	NULL
cloned	NULL
(	NULL
Kieran	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
subunit	NULL
(	NULL
p50	NULL
)	NULL
of	NULL
NF-xB	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1989	NULL
)	NULL
and	NULL
KBF1	NULL
are	NULL
indistinguishable	NULL
and	NULL
that	NULL
they	NULL
belong	NULL
to	NULL
a	NULL
family	NULL
of	NULL
structurally	NULL
related	NULL
factors	NULL
that	NULL
also	NULL
contains	NULL
the	NULL
c-	NULL
and	NULL
v-rel	NULL
(	NULL
proto	NULL
)	NULL
oncogenes	NULL
and	NULL
the	NULL
Drosophila	NULL
dorsal	NULL
gene	NULL
products	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
see	NULL
also	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
Gilmore	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
factor	NULL
NF-xB	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
xB	NULL
site	NULL
located	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
gene	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986	NULL
)	NULL
and	NULL
to	NULL
the	NULL
enhancer	NULL
A	NULL
sequence	NULL
of	NULL
H-2K	NULL
``	NULL
(	NULL
Baldwin	NULL
and	NULL
Sharp	NULL
,	NULL
1988	NULL
)	NULL
is	NULL
composed	NULL
of	NULL
two	NULL
different	NULL
subunits	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1989	NULL
)	NULL
:	NULL
a	NULL
50	NULL
kd	NULL
DNA	NULL
binding	NULL
subunit	NULL
(	NULL
KBF1/p50	NULL
)	NULL
and	NULL
a	NULL
non-DNA	NULL
binding	NULL
65	NULL
kd	NULL
subunit	NULL
(	NULL
p65	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
inactive	NULL
form	NULL
of	NULL
NF-xB	NULL
is	NULL
composed	NULL
of	NULL
p50	NULL
,	NULL
p65	NULL
and	NULL
IxB	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

IxB	NULL
inhibits	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NF-xB	NULL
and	NULL
prevents	NULL
its	NULL
translocation	NULL
into	NULL
the	NULL
nucleus	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
KBF1/p50	NULL
is	NULL
also	NULL
controlled	NULL
by	NULL
a	NULL
proteolytic	NULL
event	NULL
which	NULL
releases	NULL
p50	NULL
from	NULL
a	NULL
105	NULL
kd	NULL
precursor	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Many	NULL
transcription	NULL
factors	NULL
bind	NULL
DNA	NULL
as	NULL
dimers	NULL
and	NULL
they	NULL
can	NULL
form	NULL
heterodimers	NULL
with	NULL
other	NULL
members	NULL
of	NULL
the	NULL
same	NULL
family	NULL
(	NULL
Jun/Fos	NULL
:	NULL
Turner	NULL
and	NULL
Tjian	NULL
,	NULL
1989	NULL
;	NULL
MyoD/Id	NULL
:	NULL
Benezra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
retinoic	NULL
acid/thyroid	NULL
hormone	NULL
receptor	NULL
:	NULL
Glass	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
different	NULL
monomers	NULL
may	NULL
have	NULL
different	NULL
transcriptional	NULL
effects	NULL
(	NULL
Jones	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Our	NULL
previous	NULL
results	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
demonstrate	NULL
that	NULL
KBF1/p50	NULL
binds	NULL
to	NULL
its	NULL
site	NULL
as	NULL
a	NULL
dimer	NULL
and	NULL
that	NULL
KBF1/p50	NULL
and	NULL
v-rel	NULL
can	NULL
form	NULL
heterodimers	NULL
in	NULL
vitro	NULL
.	NULL

Structure-function	NULL
studies	NULL
of	NULL
different	NULL
eukaryotic	NULL
transcription	NULL
factors	NULL
have	NULL
allowed	NULL
the	NULL
defining	NULL
of	NULL
a	NULL
certain	NULL
number	NULL
of	NULL
specific	NULL
motifs	NULL
responsible	NULL
for	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
(	NULL
Mitchell	NULL
and	NULL
Tjian	NULL
,	NULL
1989	NULL
;	NULL
Murre	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

KBF1/p50	NULL
contains	NULL
no	NULL
obvious	NULL
homology	NULL
with	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
domains	NULL
characterized	NULL
so	NULL
far	NULL
,	NULL
but	NULL
preliminary	NULL
experiments	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
domain	NULL
are	NULL
contained	NULL
within	NULL
amino	NULL
acids	NULL
19-367	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

We	NULL
have	NULL
assayed	NULL
various	NULL
deletion	NULL
mutants	NULL
for	NULL
either	NULL
DNA	NULL
binding	NULL
or	NULL
dimerization	NULL
ability	NULL
and	NULL
report	NULL
here	NULL
the	NULL
functional	NULL
characterization	NULL
of	NULL
a	NULL
mutant	NULL
which	NULL
allows	NULL
dimerization	NULL
but	NULL
not	NULL
DNA	NULL
binding	NULL
.	NULL

Results	NULL
A	NULL
series	NULL
of	NULL
internal	NULL
or	NULL
C-terminal	NULL
deletion	NULL
mutants	NULL
have	NULL
been	NULL
assayed	NULL
for	NULL
DNA	NULL
binding	NULL
activity	NULL
by	NULL
bandshift	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Lack	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
could	NULL
be	NULL
due	NULL
to	NULL
disruption	NULL
or	NULL
deletion	NULL
of	NULL
either	NULL
the	NULL
dimerization	NULL
or	NULL
DNA	NULL
binding	NULL
domains	NULL
(	NULL
or	NULL
both	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
decided	NULL
to	NULL
localize	NULL
the	NULL
dimerization	NULL
region	NULL
of	NULL
KBF1/p50	NULL
.	NULL

We	NULL
made	NULL
the	NULL
assumption	NULL
that	NULL
the	NULL
same	NULL
region	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
p50-p50	NULL
homodimers	NULL
and	NULL
pSO-rel	NULL
heterodimers	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
strong	NULL
sequence	NULL
conservation	NULL
between	NULL
p50	NULL
and	NULL
rel	NULL
products	NULL
,	NULL
and	NULL
assayed	NULL
various	NULL
deletion	NULL
mutants	NULL
of	NULL
p50	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
associate	NULL
with	NULL
full-length	NULL
v-	NULL
or	NULL
c-rel	NULL
.	NULL

Association	NULL
was	NULL
first	NULL
evaluated	NULL
by	NULL
co-immunoprecipitation	NULL
of	NULL
v-	NULL
or	NULL
c-rel	NULL
,	NULL
using	NULL
an	NULL
anti-KBF1/p50	NULL
antiserum	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
or	NULL
anti-v-rel	NULL
(	NULL
Rice	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
or	NULL
anti-c-rel	NULL
(	NULL
Brownell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
antisera	NULL
.	NULL

The	NULL
critical	NULL
DNA	NULL
constructs	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
.	NULL

After	NULL
in	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
,	NULL
dimerization	NULL
was	NULL
tested	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
,	NULL
and	NULL
the	NULL
results	NULL
are	NULL
1827	NULL
F.Logeat	NULL
et	NULL
al	NULL
.	NULL

shown	NULL
in	NULL
Figure	NULL
2	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
we	NULL
used	NULL
the	NULL
Xba	NULL
construct	NULL
which	NULL
codes	NULL
for	NULL
a	NULL
protein	NULL
(	NULL
amino	NULL
acids	NULL
1-502	NULL
)	NULL
slightly	NULL
larger	NULL
than	NULL
p50	NULL
.	NULL

This	NULL
protein	NULL
can	NULL
be	NULL
immunoprecipitated	NULL
by	NULL
anti-p50	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
lane	NULL
6	NULL
compared	NULL
with	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
this	NULL
construct	NULL
can	NULL
associate	NULL
with	NULL
c-rel	NULL
.	NULL

The	NULL
Taq	NULL
construct	NULL
(	NULL
amino	NULL
acids	NULL
287-502	NULL
)	NULL
does	NULL
not	NULL
co-immunoprecipitate	NULL
with	NULL
c-rel	NULL
using	NULL
anti-c-rel	NULL
antiserum	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
conversely	NULL
c-rel	NULL
was	NULL
not	NULL
co-precipitated	NULL
with	NULL
Taq	NULL
using	NULL
anti-p50	NULL
antiserum	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Results	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
similarly	NULL
demonstrate	NULL
that	NULL
the	NULL
Spe	NULL
construct	NULL
(	NULL
amino	NULL
acids	NULL
1-341	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
can	NULL
not	NULL
associate	NULL
with	NULL
c-rel	NULL
.	NULL

Similarly	NULL
the	NULL
NH	NULL
construct	NULL
(	NULL
amino	NULL
acids	NULL
253-361	NULL
)	NULL
can	NULL
not	NULL
associate	NULL
with	NULL
v-rel	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
results	NULL
obtained	NULL
by	NULL
co-immunoprecipitation	NULL
we	NULL
assayed	NULL
homodimer	NULL
formation	NULL
by	NULL
glutaraldehyde	NULL
crosslinking	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
products	NULL
followed	NULL
by	NULL
immunoprecipita-tion	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
Figure	NULL
3	NULL
indicate	NULL
that	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
the	NULL
Xba	NULL
construct	NULL
is	NULL
able	NULL
to	NULL
dimerize	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Conversely	NULL
,	NULL
the	NULL
NH	NULL
construct	NULL
which	NULL
is	NULL
unable	NULL
to	NULL
form	NULL
heterodimers	NULL
with	NULL
v-	NULL
or	NULL
c-rel	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
is	NULL
also	NULL
unable	NULL
to	NULL
homodimerize	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
have	NULL
been	NULL
obtained	NULL
with	NULL
the	NULL
Taq	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
and	NULL
Spe	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
constructs	NULL
.	NULL

These	NULL
results	NULL
support	NULL
our	NULL
initial	NULL
hypothesis	NULL
that	NULL
the	NULL
same	NULL
domain	NULL
is	NULL
used	NULL
for	NULL
p50-p50	NULL
homodimer	NULL
formation	NULL
and	NULL
p50-rel	NULL
heterodimerization	NULL
.	NULL

Construct	NULL
name	NULL
'	NULL
_	NULL
oops	NULL
___	NULL
502	NULL
Xba	NULL
1	NULL
341	NULL
Spe	NULL
1_10	NULL
287	NULL
___	NULL
502	NULL
Tag	NULL
110	NULL
_	NULL
201	NULL
502	NULL
ASP	NULL
253	NULL
361	NULL
NH	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Schematic	NULL
diagram	NULL
of	NULL
the	NULL
constructs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Relevant	NULL
amino	NULL
acid	NULL
numbers	NULL
are	NULL
indicated	NULL
.	NULL

Shaded	NULL
box	NULL
:	NULL
rel	NULL
homology	NULL
region	NULL
.	NULL

We	NULL
then	NULL
assayed	NULL
by	NULL
co-immunoprecipitation	NULL
the	NULL
ASP	NULL
construct	NULL
which	NULL
corresponds	NULL
to	NULL
a	NULL
deletion	NULL
of	NULL
amino	NULL
acids	NULL
11-200	NULL
in	NULL
the	NULL
Xba	NULL
construct	NULL
;	NULL
this	NULL
deletion	NULL
mutant	NULL
can	NULL
associate	NULL
with	NULL
v-rel	NULL
(	NULL
Figure	NULL
4	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
although	NULL
it	NULL
is	NULL
not	NULL
able	NULL
to	NULL
bind	NULL
DNA	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
show	NULL
that	NULL
ASP	NULL
is	NULL
correctly	NULL
recognized	NULL
by	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
,	NULL
and	NULL
lane	NULL
5	NULL
shows	NULL
that	NULL
v-rel	NULL
is	NULL
not	NULL
recognized	NULL
by	NULL
this	NULL
antiserum	NULL
.	NULL

Oligomeric	NULL
proteins	NULL
which	NULL
contain	NULL
independent	NULL
functional	NULL
domains	NULL
can	NULL
be	NULL
inhibited	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
by	NULL
a	NULL
non-DNA	NULL
binding	NULL
mutant	NULL
which	NULL
has	NULL
retained	NULL
its	NULL
dimerization	NULL
domain	NULL
(	NULL
Herskowitz	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

We	NULL
asked	NULL
first	NULL
if	NULL
the	NULL
ASP	NULL
mutant	NULL
could	NULL
act	NULL
as	NULL
a	NULL
transdominant	NULL
inhibitor	NULL
of	NULL
the	NULL
wild-type	NULL
in	NULL
vitro	NULL
.	NULL

Various	NULL
concentrations	NULL
of	NULL
ASP	NULL
RNA	NULL
were	NULL
co-translated	NULL
with	NULL
a	NULL
constant	NULL
amount	NULL
of	NULL
the	NULL
Xba	NULL
construct	NULL
RNA	NULL
(	NULL
wild-type	NULL
form	NULL
:	NULL
Figure	NULL
5A	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
or	NULL
of	NULL
the	NULL
v-rel	NULL
construct	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
or	NULL
of	NULL
the	NULL
c-rel	NULL
construct	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
,	NULL
ASP	NULL
is	NULL
able	NULL
to	NULL
inhibit	NULL
binding	NULL
of	NULL
the	NULL
Xba	NULL
product	NULL
to	NULL
the	NULL
H-2K°	NULL
``	NULL
site	NULL
when	NULL
assayed	NULL
in	NULL
a	NULL
gel-shift	NULL
assay	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
can	NULL
be	NULL
obtained	NULL
with	NULL
v-rel	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
and	NULL
with	NULL
c-rel	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

We	NULL
then	NULL
assayed	NULL
the	NULL
in	NULL
vivo	NULL
effect	NULL
of	NULL
the	NULL
ASP	NULL
mutant	NULL
by	NULL
asking	NULL
whether	NULL
its	NULL
product	NULL
could	NULL
inhibit	NULL
in	NULL
vivo	NULL
the	NULL
binding	NULL
of	NULL
KBF1/p50	NULL
or	NULL
NF-xB	NULL
to	NULL
their	NULL
consensus	NULL
sequence	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
a	NULL
detectable	NULL
inhibition	NULL
of	NULL
transcriptional	NULL
activity	NULL
.	NULL

We	NULL
decided	NULL
to	NULL
test	NULL
first	NULL
whether	NULL
the	NULL
introduction	NULL
of	NULL
an	NULL
expression	NULL
vector	NULL
coding	NULL
for	NULL
ASP	NULL
in	NULL
T	NULL
cells	NULL
could	NULL
prevent	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-xB	NULL
dependent	NULL
enhancer	NULL
of	NULL
HIV-1	NULL
.	NULL

With	NULL
this	NULL
aim	NULL
,	NULL
we	NULL
transfected	NULL
J.Jhan	NULL
T	NULL
cells	NULL
,	NULL
either	NULL
with	NULL
the	NULL
plasmid	NULL
LTR-luc	NULL
(	NULL
where	NULL
the	NULL
reporter	NULL
gene	NULL
luciferase	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
)	NULL
or	NULL
with	NULL
3-Enh-TK-luc	NULL
(	NULL
where	NULL
three	NULL
copies	NULL
of	NULL
HIV-1	NULL
enhancer	NULL
are	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
herpes	NULL
virus-1	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
in	NULL
the	NULL
TK-luc	NULL
vector	NULL
;	NULL
see	NULL
Materials	NULL
and	NULL
methods	NULL
)	NULL
(	NULL
Schwartz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
(	NULL
Nabel	NULL
and	NULL
Baltimore	NULL
,	NULL
1987	NULL
)	NULL
,	NULL
addition	NULL
of	NULL
phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
)	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
resulted	NULL
in	NULL
a	NULL
reproducible	NULL
enhancement	NULL
of	NULL
luciferase	NULL
activity	NULL
with	NULL
either	NULL
plasmid	NULL
.	NULL

The	NULL
amplifications	NULL
obtained	NULL
were	NULL
respectively	NULL
7-	NULL
and	NULL
12-fold	NULL
when	NULL
LTR-luc	NULL
and	NULL
3-Enh-TK-luc	NULL
were	NULL
used	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
stimulation	NULL
effect	NULL
was	NULL
decreased	NULL
when	NULL
the	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Co-immunoprecipitation	NULL
of	NULL
c-rel	NULL
with	NULL
KBF1/pS50	NULL
constructs	NULL
.	NULL

The	NULL
cDNAs	NULL
encoded	NULL
by	NULL
the	NULL
constructs	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
were	NULL
co-translated	NULL
either	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
c-rel	NULL
cDNA	NULL
in	NULL
wheat	NULL
germ	NULL
extracts	NULL
,	NULL
and	NULL
immunoprecipitated	NULL
by	NULL
anti-KBF1/pS50	NULL
polyclonal	NULL
antiserum	NULL
No	NULL
.	NULL

2	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
or	NULL
with	NULL
anti-c-rel	NULL
antiserum	NULL
(	NULL
Rice	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Brownell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
(	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
on	NULL
12	NULL
%	NULL
Tricine-SDS-polyacrylamide	NULL
gels	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

wt	NULL
markers	NULL
(	NULL
kd	NULL
)	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
side	NULL
.	NULL

A	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
co-translated	NULL
Taq	NULL
and	NULL
c-rel	NULL
constructs	NULL
with	NULL
the	NULL
anti-c-rel	NULL
antiserum	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
same	NULL
products	NULL
immunoprecipitated	NULL
with	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
No	NULL
.	NULL

2	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
Taq	NULL
construct	NULL
with	NULL
anti-c-rel	NULL
antiserum	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
c-rel	NULL
construct	NULL
with	NULL
the	NULL
anti-c-rel	NULL
antiserum	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
c-rel	NULL
construct	NULL
with	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
co-translated	NULL
Xba	NULL
and	NULL
c-rel	NULL
constructs	NULL
with	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
.	NULL

B	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
co-translated	NULL
Spe	NULL
and	NULL
c-rel	NULL
with	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
same	NULL
products	NULL
immunoprecipitated	NULL
with	NULL
the	NULL
anti-c-rel	NULL
antiserum	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
c-rel	NULL
product	NULL
with	NULL
the	NULL
anti-c-rel	NULL
antiserum	NULL
.	NULL

The	NULL
two	NULL
bands	NULL
labeled	NULL
c-rel	NULL
correspond	NULL
to	NULL
the	NULL
full-length	NULL
protein	NULL
(	NULL
upper	NULL
band	NULL
)	NULL
and	NULL
to	NULL
a	NULL
truncated	NULL
form	NULL
probably	NULL
caused	NULL
by	NULL
premature	NULL
termination	NULL
(	NULL
lower	NULL
band	NULL
)	NULL
.	NULL

C.	NULL
Lane	NULL
1	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
co-translated	NULL
NH	NULL
and	NULL
v-rel	NULL
constructs	NULL
with	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
NH	NULL
construct	NULL
with	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
co-translated	NULL
NH	NULL
and	NULL
v-rel	NULL
constructs	NULL
with	NULL
the	NULL
anti-v-rel	NULL
antiserum	NULL
.	NULL

1828	NULL
CMV-ASP	NULL
construct	NULL
(	NULL
where	NULL
the	NULL
ASP	NULL
cDNA	NULL
has	NULL
been	NULL
cloned	NULL
downstream	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
promoter/enhancer	NULL
)	NULL
was	NULL
co-transfected	NULL
(	NULL
Figure	NULL
6	NULL
,	NULL
lower	NULL
panels	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
inhibition	NULL
of	NULL
the	NULL
induced	NULL
activity	NULL
of	NULL
both	NULL
constructs	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
concentration	NULL
of	NULL
CMV-ASP	NULL
DNA	NULL
used	NULL
in	NULL
the	NULL
co-transfection	NULL
assays	NULL
.	NULL

With	NULL
both	NULL
luciferase	NULL
expression	NULL
vectors	NULL
,	NULL
the	NULL
inhibition	NULL
reached	NULL
~80	NULL
%	NULL
with	NULL
the	NULL
highest	NULL
concentration	NULL
of	NULL
CMV-ASP	NULL
DNA	NULL
used	NULL
(	NULL
corresponding	NULL
to	NULL
a	NULL
ratio	NULL
of	NULL
6.7	NULL
between	NULL
CMV-ASP	NULL
and	NULL
the	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
we	NULL
replaced	NULL
CMV-ASP	NULL
by	NULL
the	NULL
vector	NULL
Rc-CMV	NULL
,	NULL
which	NULL
contains	NULL
no	NULL
cDNA	NULL
sequence	NULL
.	NULL

We	NULL
did	NULL
not	NULL
observe	NULL
significant	NULL
variations	NULL
in	NULL
luciferase	NULL
activity	NULL
,	NULL
regardless	NULL
of	NULL
the	NULL
plasmid	NULL
concentration	NULL
(	NULL
upper	NULL
panels	NULL
)	NULL
.	NULL

We	NULL
performed	NULL
similar	NULL
competition	NULL
experiments	NULL
using	NULL
the	NULL
enhancer	NULL
or	NULL
promoter	NULL
of	NULL
the	NULL
mouse	NULL
MHC	NULL
class	NULL
I	NULL
H-2K	NULL
``	NULL
®	NULL
gene	NULL
in	NULL
HeLa	NULL
and	NULL
Cos-7	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

It	NULL
can	NULL
be	NULL
seen	NULL
that	NULL
both	NULL
a	NULL
promoter	NULL
(	NULL
containing	NULL
potential	NULL
NF-xB	NULL
binding	NULL
sites	NULL
;	NULL
Israél	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989b	NULL
)	NULL
and	NULL
an	NULL
enhancer	NULL
construct	NULL
derived	NULL
from	NULL
the	NULL
H-2K	NULL
``	NULL
promoter	NULL
were	NULL
efficiently	NULL
inhibited	NULL
by	NULL
a	NULL
five	NULL
times	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
CMV-ASP	NULL
construct	NULL
.	NULL

The	NULL
inhibition	NULL
observed	NULL
with	NULL
the	NULL
promoter	NULL
construct	NULL
was	NULL
not	NULL
as	NULL
strong	NULL
as	NULL
with	NULL
the	NULL
enhancer	NULL
construct	NULL
,	NULL
probably	NULL
due	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
there	NULL
are	NULL
other	NULL
elements	NULL
involved	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
17	NULL
8	NULL
+	NULL
+	NULL
+	NULL
_+	NULL
D=	NULL
-_92	NULL
-69	NULL
M-	NULL
qweup	NULL
46	NULL
case	NULL
a	NULL
~	NULL
-30	NULL
<	NULL
%	NULL
_21	NULL
n	NULL
-14	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Glutaraldehyde	NULL
crosslinking	NULL
of	NULL
KBF1/p50	NULL
products	NULL
.	NULL

In	NULL
vitro	NULL
translated	NULL
proteins	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
glutaraldehyde	NULL
(	NULL
+	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
,	NULL
followed	NULL
by	NULL
analysis	NULL
on	NULL
Tricine-SDS-polyacrylamide	NULL
gels	NULL
:	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
Xba	NULL
construct	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
Taq	NULL
construct	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
NH	NULL
construct	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
,	NULL
Spe	NULL
construct	NULL
.	NULL

M	NULL
:	NULL
monomer	NULL
.	NULL

D	NULL
:	NULL
dimer	NULL
.	NULL

1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
<	NULL
4	NULL
69	NULL
|	NULL
<	NULL
€	NULL
46	NULL
}	NULL
-	NULL
Allg	NULL
<	NULL
21	NULL
TB	NULL
same	NULL
~	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Co-immunoprecipitation	NULL
of	NULL
the	NULL
v-rel	NULL
and	NULL
ASP	NULL
products	NULL
.	NULL

The	NULL
ASP	NULL
construct	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
was	NULL
translated	NULL
either	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
the	NULL
v-rel	NULL
cDNA	NULL
in	NULL
wheat	NULL
germ	NULL
extracts	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-p50	NULL
or	NULL
anti-v-rel	NULL
antiserum	NULL
(	NULL
Brownell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
10	NULL
%	NULL
SDS	NULL
-polyacrylamide	NULL
gel	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
ASP	NULL
by	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
one-fifth	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
as	NULL
in	NULL
lane	NULL
1	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
co-translated	NULL
ASP	NULL
and	NULL
v-rel	NULL
by	NULL
the	NULL
anti-p50	NULL
antiserum	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
v-rel	NULL
by	NULL
anti-v-rel	NULL
antiserum	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
v-rel	NULL
by	NULL
anti-p50	NULL
antiserum	NULL
.	NULL

A	NULL
transdominant	NULL
negative	NULL
mutant	NULL
of	NULL
rel/NF-xB	NULL
in	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
H-2K	NULL
``	NULL
promoter	NULL
in	NULL
the	NULL
393	NULL
bp	NULL
of	NULL
the	NULL
(	NULL
393	NULL
)	NULL
H2-CAT	NULL
construct	NULL
(	NULL
Kimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Interestingly	NULL
both	NULL
basal	NULL
and	NULL
induced	NULL
levels	NULL
of	NULL
the	NULL
K®	NULL
promoter	NULL
were	NULL
inhibited	NULL
by	NULL
the	NULL
ASP	NULL
construct	NULL
.	NULL

Induction	NULL
of	NULL
K°	NULL
expression	NULL
by	NULL
TNF	NULL
(	NULL
Tumor	NULL
Necrosis	NULL
Factor	NULL
)	NULL
in	NULL
HeLa	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
due	NULL
to	NULL
binding	NULL
of	NULL
NF-xB	NULL
to	NULL
the	NULL
enhancer	NULL
sequence	NULL
while	NULL
KBF1/p50	NULL
(	NULL
and	NULL
possibly	NULL
AP2	NULL
)	NULL
are	NULL
probably	NULL
responsible	NULL
for	NULL
basal	NULL
level	NULL
of	NULL
expression	NULL
(	NULL
Israél	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989b	NULL
)	NULL
.	NULL

For	NULL
the	NULL
Cos-7	NULL
cells	NULL
induction	NULL
experiments	NULL
we	NULL
have	NULL
used	NULL
interleukin	NULL
1	NULL
(	NULL
IL1	NULL
)	NULL
instead	NULL
of	NULL
TNF	NULL
because	NULL
the	NULL
stimulation	NULL
observed	NULL
was	NULL
much	NULL
stronger	NULL
;	NULL
bandshift	NULL
assays	NULL
have	NULL
demonstrated	NULL
that	NULL
IL-1	NULL
treatment	NULL
resulted	NULL
in	NULL
NF-xB	NULL
induction	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
inhibition	NULL
is	NULL
more	NULL
swe	NULL
-a	NULL
[	NULL
\	NULL
O	NULL
T	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Transdominant	NULL
suppression	NULL
of	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
following	NULL
RNAs	NULL
were	NULL
translated	NULL
in	NULL
wheat	NULL
germ	NULL
extracts	NULL
and	NULL
the	NULL
products	NULL
were	NULL
either	NULL
analyzed	NULL
by	NULL
PAGE	NULL
on	NULL
10	NULL
%	NULL
gels	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
or	NULL
assayed	NULL
by	NULL
retardation	NULL
using	NULL
the	NULL
H-2K®	NULL
palindrome	NULL
KBF1	NULL
binding	NULL
site	NULL
as	NULL
described	NULL
in	NULL
Kieran	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

Panels	NULL
A	NULL
and	NULL
B	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
1	NULL
ul	NULL
of	NULL
Xba	NULL
RNA	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
Xba	NULL
RNA	NULL
+	NULL
0.5	NULL
gl	NULL
of	NULL
ASP	NULL
RNA	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
Xba	NULL
RNA	NULL
+	NULL
1	NULL
ul	NULL
of	NULL
ASP	NULL
RNA	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
1	NULL
al	NULL
of	NULL
Xba	NULL
RNA	NULL
+3	NULL
pl	NULL
of	NULL
ASP	NULL
RNA	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
0.6	NULL
al	NULL
of	NULL
v-rel	NULL
RNA	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
0.6	NULL
Ll	NULL
of	NULL
v-rel	NULL
RNA	NULL
+	NULL
0.5	NULL
ul	NULL
of	NULL
ASP	NULL
RNA	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
0.6	NULL
al	NULL
of	NULL
v-rel	NULL
RNA	NULL
+	NULL
1	NULL
pl	NULL
of	NULL
ASP	NULL
RNA	NULL
:	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
1	NULL
gl	NULL
of	NULL
ASP	NULL
RNA	NULL
.	NULL

Panel	NULL
B	NULL
only	NULL
:	NULL
lane	NULL
9	NULL
.	NULL

1	NULL
4	NULL
1	NULL
of	NULL
c-rel	NULL
RNA	NULL
;	NULL
lane	NULL
10	NULL
,	NULL
1	NULL
gl	NULL
of	NULL
c-rel	NULL
RNA	NULL
+	NULL
2	NULL
gl	NULL
of	NULL
ASP	NULL
RNA	NULL
;	NULL
lane	NULL
N	NULL
,	NULL
1	NULL
al	NULL
of	NULL
HeLa	NULL
nuclear	NULL
extract	NULL
.	NULL

1829	NULL
F.Logeat	NULL
et	NULL
al	NULL
.	NULL

1000	NULL
za	NULL
&	NULL
LACALALS	NULL
2.2	NULL
,	NULL
2	NULL
,	NULL
2	NULL
,	NULL
4	NULL
2.2	NULL
.	NULL

2	NULL
2	NULL
:5°°	NULL
SSS	NULL
OX	NULL
S	NULL
Al	NULL
NOS	NULL
Lop	NULL
SE	NULL
SAS	NULL
s	NULL
AA	NULL
,	NULL
Aae	NULL
?	NULL

RA	NULL
>	NULL
&	NULL
's	NULL
's	NULL
s	NULL
sl	NULL
\sss	NULL
*	NULL
,	NULL
5	NULL
Raa	NULL
,	NULL
Reta	NULL
PACE	NULL
o	NULL
£	NULL
sC	NULL
8	NULL
Sy	NULL
is	NULL
A	NULL
soo	NULL
RAR	NULL
AAARARA	NULL
AA	NULL
,	NULL
&	NULL
O8	NULL
LSAS	NULL
:	NULL
&	NULL
2.2.2.2	NULL
2	NULL
.	NULL

2.2.2	NULL
,	NULL
A	NULL
2.2	NULL
2.2	NULL
in	NULL
sys	NULL
SISOS	NULL
8	NULL
AAR	NULL
,	NULL
Aas	NULL
?	NULL

Fal	NULL
's	NULL
'	NULL
&	NULL
ao	NULL
\r\z	NULL
/\I	NULL
z\/\/\z\	NULL
\'\'\'\'~	NULL
~	NULL
a	NULL
2/2022	NULL
)	NULL
2020202	NULL
o	NULL
OS	NULL
Af	NULL
so	NULL
5	NULL
LALAAL	NULL
LAAALAL	NULL
-_	NULL
200	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2/2	NULL
22	NULL
SOSA	NULL
O8	NULL
SOs	NULL
80s	NULL
A	NULL
2.2.2.2	NULL
2	NULL
.	NULL

2	NULL
.	NULL

2	NULL
.	NULL

2	NULL
,	NULL
A	NULL
2.2.2.2	NULL
\\\	NULL
'S	NULL
Pce	NULL
Peoe	NULL
ol	NULL
a	NULL
's	NULL
's	NULL
``	NULL
s	NULL
``	NULL
w	NULL
's	NULL
``	NULL
,	NULL
&	NULL
.	NULL

+	NULL
LTR	NULL
LTR®Rc	NULL
1x	NULL
-	NULL
LTR*Rc	NULL
3x	NULL
6,78	NULL
Luciferase	NULL
activity	NULL
LTR	NULL
1X	NULL
-	NULL
LTR+aSP	NULL
3X	NULL
LTR+ASP	NULL
6,7X	NULL
200	NULL
yer	NULL
1500	NULL
*N	NULL
\*s	NULL
's	NULL
'	NULL
SUS	NULL
2	NULL
pel	NULL
2	NULL
20+	NULL
SSCs	NULL
is	NULL
ysis	NULL
8	NULL
a	NULL
2202204	NULL
ple	NULL
lz	NULL
Wife	NULL
ahs	NULL
Niss	NULL
2	NULL
2	NULL
(	NULL
2	NULL
24	NULL
2	NULL
a	NULL
ple	NULL
cece	NULL
sof	NULL
o	NULL
S	NULL
sh	NULL
Nia	NULL
100	NULL
2	NULL
,	NULL
20202	NULL
2	NULL
2.2	NULL
2.2.2.7	NULL
,	NULL
S	NULL
2	NULL
)	NULL
e	NULL
ele	NULL
ee	NULL
2	NULL
elz	NULL
Lx	NULL
Sh	NULL
SKS	NULL
NSC	NULL
nial	NULL
2	NULL
)	NULL
2022	NULL
p	NULL
z	NULL
le	NULL
(	NULL
elz	NULL
NSCs	NULL
iA	NULL
os	NULL
HEAL	NULL
2	NULL
le	NULL
222	NULL
ale	NULL
cece	NULL
500	NULL
S	NULL
wiith	NULL
NCSS	NULL
Sal	NULL
SCSCS	NULL
CSAs	NULL
SSC	NULL
SCS	NULL
202	NULL
2	NULL
ez	NULL
2.2	NULL
s	NULL
NSs	NULL
cs	NULL
Sa	NULL
2	NULL
e	NULL
2	NULL
)	NULL
LAAL	NULL
ale	NULL
lace	NULL
a+	NULL
E	NULL
E+Rc	NULL
IX	NULL
E+Rc	NULL
3X	NULL
E+Rc	NULL
6,78	NULL
E	NULL
E+ASP	NULL
1X	NULL
E+ASP	NULL
3X	NULL
E+ASP	NULL
6,78	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
enhancer	NULL
or	NULL
promoter	NULL
activation	NULL
by	NULL
the	NULL
CMV-ASP	NULL
construct	NULL
.	NULL

J.Jhan	NULL
cells	NULL
(	NULL
4	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
co-transfected	NULL
either	NULL
with	NULL
Rc-CMV	NULL
(	NULL
upper	NULL
panels	NULL
)	NULL
or	NULL
with	NULL
CMV-ASP	NULL
(	NULL
lower	NULL
panels	NULL
)	NULL
in	NULL
various	NULL
amounts	NULL
,	NULL
together	NULL
with	NULL
a	NULL
fixed	NULL
amount	NULL
of	NULL
LTR-luc	NULL
(	NULL
left	NULL
panels	NULL
)	NULL
of	NULL
3-Enh-TK-luc	NULL
(	NULL
right	NULL
panels	NULL
;	NULL
E	NULL
refers	NULL
to	NULL
the	NULL
3-Enh-TK-luc	NULL
plasmid	NULL
)	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
PMA	NULL
from	NULL
24	NULL
to	NULL
40	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
after	NULL
which	NULL
the	NULL
cells	NULL
were	NULL
processed	NULL
for	NULL
luciferase	NULL
assay	NULL
.	NULL

The	NULL
ratio	NULL
between	NULL
the	NULL
competitor	NULL
(	NULL
Re	NULL
refers	NULL
to	NULL
the	NULL
Rc-CMV	NULL
vector	NULL
,	NULL
ASP	NULL
to	NULL
the	NULL
CMV-ASP	NULL
expression	NULL
vector	NULL
coding	NULL
for	NULL
the	NULL
ASP	NULL
mutant	NULL
)	NULL
and	NULL
the	NULL
test	NULL
plasmid	NULL
is	NULL
indicated	NULL
under	NULL
the	NULL
histogram	NULL
bars	NULL
.	NULL

Each	NULL
bar	NULL
represents	NULL
the	NULL
mean	NULL
of	NULL
luciferase	NULL
activities	NULL
obtained	NULL
in	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
standard	NULL
deviation	NULL
never	NULL
exceeded	NULL
10	NULL
%	NULL
.	NULL

efficient	NULL
when	NULL
cells	NULL
are	NULL
induced	NULL
,	NULL
suggesting	NULL
that	NULL
under	NULL
these	NULL
conditions	NULL
the	NULL
enhancer	NULL
region	NULL
plays	NULL
a	NULL
more	NULL
prominent	NULL
role	NULL
in	NULL
the	NULL
overall	NULL
promoter	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
ASP	NULL
mutant	NULL
can	NULL
inhibit	NULL
both	NULL
KBF1/p50	NULL
and	NULL
NF-xB	NULL
activities	NULL
in	NULL
vivo	NULL
(	NULL
see	NULL
Israel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989b	NULL
,	NULL
and	NULL
Discussion	NULL
)	NULL
.	NULL

Discussion	NULL
Experiments	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
the	NULL
dimerization	NULL
domain	NULL
of	NULL
KBF1/p50	NULL
can	NULL
be	NULL
functionally	NULL
separated	NULL
from	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
.	NULL

The	NULL
dimerization	NULL
domain	NULL
is	NULL
localized	NULL
between	NULL
amino	NULL
acids	NULL
201	NULL
and	NULL
367	NULL
.	NULL

Further	NULL
studies	NULL
using	NULL
Bal	NULL
3\	NULL
digestion	NULL
and	NULL
site-directed	NULL
mutagenesis	NULL
should	NULL
allow	NULL
its	NULL
more	NULL
precise	NULL
localization	NULL
.	NULL

Recently	NULL
,	NULL
Ip	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
Drosophila	NULL
protein	NULL
dorsal	NULL
,	NULL
which	NULL
also	NULL
belongs	NULL
to	NULL
the	NULL
rel/NF-xB	NULL
family	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
NF-xB-rel	NULL
homology	NULL
region	NULL
.	NULL

An	NULL
internal	NULL
deletion	NULL
between	NULL
amino	NULL
acids	NULL
245	NULL
and	NULL
325	NULL
does	NULL
not	NULL
abolish	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Although	NULL
dorsal	NULL
recognizes	NULL
sites	NULL
that	NULL
are	NULL
slightly	NULL
different	NULL
from	NULL
those	NULL
recognized	NULL
by	NULL
NF-xB	NULL
,	NULL
if	NULL
we	NULL
assume	NULL
that	NULL
the	NULL
two	NULL
proteins	NULL
use	NULL
the	NULL
same	NULL
type	NULL
of	NULL
dimerization	NULL
domain	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
this	NULL
domain	NULL
might	NULL
be	NULL
split	NULL
into	NULL
two	NULL
parts	NULL
and	NULL
that	NULL
the	NULL
region	NULL
between	NULL
amino	NULL
acids	NULL
245	NULL
and	NULL
325	NULL
in	NULL
dorsal	NULL
(	NULL
which	NULL
corresponds	NULL
to	NULL
amino	NULL
acids	NULL
270-350	NULL
of	NULL
the	NULL
KBF1/p50	NULL
protein	NULL
)	NULL
could	NULL
be	NULL
dispensable	NULL
for	NULL
dimerization	NULL
.	NULL

However	NULL
,	NULL
it	NULL
must	NULL
be	NULL
kept	NULL
in	NULL
mind	NULL
that	NULL
we	NULL
have	NULL
not	NULL
been	NULL
able	NULL
to	NULL
demonstrate	NULL
association	NULL
between	NULL
dorsal	NULL
and	NULL
KBF1/p50	NULL
by	NULL
co-immunoprecipitation	NULL
of	NULL
co-translated	NULL
proteins	NULL
using	NULL
an	NULL
anti-p50	NULL
antiserum	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Further	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
answer	NULL
those	NULL
questions	NULL
.	NULL

We	NULL
found	NULL
no	NULL
obvious	NULL
homology	NULL
with	NULL
previously	NULL
characterized	NULL
motifs	NULL
in	NULL
this	NULL
region	NULL
,	NULL
suggesting	NULL
that	NULL
KBF1/p50	NULL
,	NULL
v-rel	NULL
and	NULL
c-rel	NULL
,	NULL
which	NULL
all	NULL
can	NULL
form	NULL
heterodimers	NULL
,	NULL
1830	NULL
Table	NULL
I.	NULL
Inhibitory	NULL
effect	NULL
of	NULL
the	NULL
CMV-ASP	NULL
construct	NULL
on	NULL
MHC	NULL
class	NULL
I	NULL
H-2K	NULL
``	NULL
gene	NULL
promoter	NULL
or	NULL
enhancer	NULL
expression	NULL
in	NULL
HeLa	NULL
and	NULL
Cos-7	NULL
cells	NULL
(	NULL
ab	NULL
}	NULL
4-CAT	NULL
(	NULL
393	NULL
)	NULL
H2-CAT	NULL
Hela	NULL
Cos-7	NULL
-	NULL
Hela	NULL
Cos-7	NULL
~TNF	NULL
_	NULL
+TNF	NULL
-	NULL
-IL-4	NULL
_-	NULL
+IL-1	NULL
pUC	NULL
§	NULL
1°	NULL
§	NULL
3.5	NULL
19	NULL
5.0	NULL
Re-CMV	NULL
_	NULL
0.950	NULL
0	NULL
0.80	NULL
_	NULL
d	NULL
3.0	NULL
0.9	NULL
3.8	NULL
CMV-ASP	NULL
0.24	NULL
-	NULL
041	NULL
_	NULL
0.6	NULL
1.1	NULL
0.5	NULL
0.5	NULL
2	NULL
ug	NULL
of	NULL
each	NULL
CAT	NULL
construct	NULL
was	NULL
co-translated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
either	NULL
pUC	NULL
(	NULL
negative	NULL
control	NULL
)	NULL
,	NULL
Re-CMV	NULL
(	NULL
to	NULL
assay	NULL
possible	NULL
promoter	NULL
competition	NULL
)	NULL
or	NULL
CMV-ASP	NULL
.	NULL

2	NULL
ug	NULL
of	NULL
RSV-f	NULL
@	NULL
gal	NULL
was	NULL
co-transfected	NULL
in	NULL
each	NULL
case	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
TNF	NULL
(	NULL
500	NULL
U/ml	NULL
:	NULL
HeLa	NULL
cells	NULL
)	NULL
or	NULL
IL-1	NULL
(	NULL
100	NULL
U/ml	NULL
:	NULL
Cos-7	NULL
cells	NULL
)	NULL
during	NULL
the	NULL
last	NULL
16	NULL
h	NULL
before	NULL
collection	NULL
.	NULL

Cytoplasmic	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
activities	NULL
were	NULL
measured	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
normalized	NULL
according	NULL
to	NULL
the	NULL
B-gal	NULL
activity	NULL
.	NULL

The	NULL
table	NULL
presents	NULL
the	NULL
results	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
;	NULL
variation	NULL
between	NULL
the	NULL
observed	NULL
inhibition	NULL
values	NULL
was	NULL
<	NULL
20	NULL
%	NULL
.	NULL

*These	NULL
values	NULL
were	NULL
arbitrarily	NULL
taken	NULL
as	NULL
1	NULL
,	NULL
the	NULL
actual	NULL
values	NULL
were	NULL
:	NULL
*3	NULL
CAT	NULL
units/mg	NULL
protein	NULL
(	NULL
one	NULL
unit	NULL
corresponds	NULL
to	NULL
1	NULL
nmol	NULL
of	NULL
acetylated	NULL
chloramphenicol/h	NULL
)	NULL
;	NULL
°8	NULL
units/mg	NULL
protein	NULL
;	NULL
0.8	NULL
units/mg	NULL
protein	NULL
;	NULL
1.8	NULL
units/mg	NULL
protein	NULL
.	NULL

use	NULL
a	NULL
novel	NULL
type	NULL
of	NULL
dimerization	NULL
domain	NULL
.	NULL

The	NULL
internally	NULL
deleted	NULL
construct	NULL
ASP	NULL
,	NULL
which	NULL
can	NULL
not	NULL
bind	NULL
DNA	NULL
but	NULL
can	NULL
form	NULL
homo-	NULL
or	NULL
heterodimers	NULL
(	NULL
with	NULL
KBF1/p50	NULL
or	NULL
c-	NULL
or	NULL
v-rel	NULL
)	NULL
can	NULL
inhibit	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
wild-type	NULL
construct	NULL
in	NULL
vitro	NULL
by	NULL
forming	NULL
inactive	NULL
heterodimers	NULL
.	NULL

The	NULL
same	NULL
construct	NULL
acts	NULL
in	NULL
vivo	NULL
by	NULL
inhibiting	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
promoter	NULL
or	NULL
promoter	NULL
elements	NULL
which	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
bind	NULL
KBF1/p50	NULL
or	NULL
NF-xB	NULL
,	NULL
most	NULL
likely	NULL
by	NULL
the	NULL
same	NULL
mechanism	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
each	NULL
monomer	NULL
is	NULL
required	NULL
for	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

However	NULL
,	NULL
this	NULL
does	NULL
not	NULL
necessarily	NULL
imply	NULL
that	NULL
the	NULL
NF-xB	NULL
complex	NULL
uses	NULL
the	NULL
same	NULL
surfaces	NULL
to	NULL
contact	NULL
DNA	NULL
.	NULL

The	NULL
recent	NULL
observation	NULL
that	NULL
the	NULL
p65	NULL
protein	NULL
is	NULL
also	NULL
related	NULL
to	NULL
the	NULL
rel	NULL
family	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
clear-cut	NULL
differences	NULL
observed	NULL
between	NULL
KBF1/p50	NULL
and	NULL
NF-xB	NULL
in	NULL
their	NULL
respective	NULL
DNA	NULL
binding	NULL
properties	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
might	NULL
suggest	NULL
a	NULL
situation	NULL
similar	NULL
to	NULL
the	NULL
jun-fos	NULL
system	NULL
(	NULL
Turner	NULL
and	NULL
Tjian	NULL
,	NULL
1989	NULL
)	NULL
where	NULL
p50	NULL
and	NULL
p65	NULL
would	NULL
bind	NULL
DNA	NULL
together	NULL
,	NULL
although	NULL
p65	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
able	NULL
to	NULL
bind	NULL
by	NULL
itself	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
ASP	NULL
construct	NULL
can	NULL
inhibit	NULL
both	NULL
basal	NULL
and	NULL
induced	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
genes	NULL
in	NULL
two	NULL
cell	NULL
lines	NULL
as	NULL
well	NULL
as	NULL
induced	NULL
HIV	NULL
expression	NULL
in	NULL
a	NULL
CD4*	NULL
T	NULL
cell	NULL
line	NULL
constitutes	NULL
the	NULL
first	NULL
formal	NULL
proof	NULL
that	NULL
these	NULL
cellular	NULL
or	NULL
viral	NULL
sequences	NULL
are	NULL
regulated	NULL
by	NULL
a	NULL
member	NULL
(	NULL
or	NULL
several	NULL
)	NULL
of	NULL
the	NULL
NF-xB-rel	NULL
family	NULL
.	NULL

It	NULL
has	NULL
recently	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
product	NULL
of	NULL
the	NULL
protooncogene	NULL
c-re/	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
overall	NULL
'NF-xB	NULL
'	NULL
activity	NULL
observed	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Ballard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Molitor	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Experiments	NULL
shown	NULL
in	NULL
Figure	NULL
5	NULL
suggest	NULL
that	NULL
ASP	NULL
could	NULL
inhibit	NULL
c-re/	NULL
activity	NULL
in	NULL
vivo	NULL
as	NULL
well	NULL
.	NULL

Conversely	NULL
it	NULL
suggests	NULL
that	NULL
the	NULL
previously	NULL
cloned	NULL
factors	NULL
MBP-1	NULL
(	NULL
Baldwin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
or	NULL
PRDIIBF	NULL
!	NULL

(	NULL
Fan	NULL
and	NULL
Maniatis	NULL
,	NULL
1990	NULL
)	NULL
are	NULL
probably	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
at	NULL
least	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
studied	NULL
(	NULL
which	NULL
include	NULL
for	NULL
HIV-1	NULL
a	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
line	NULL
which	NULL
is	NULL
its	NULL
physiological	NULL
host	NULL
)	NULL
,	NULL
because	NULL
their	NULL
sequences	NULL
contain	NULL
no	NULL
motif	NULL
homologous	NULL
to	NULL
rel	NULL
or	NULL
KBF1/p50	NULL
and	NULL
most	NULL
likely	NULL
could	NULL
not	NULL
form	NULL
heterodimers	NULL
with	NULL
ASP	NULL
.	NULL

The	NULL
recent	NULL
observation	NULL
that	NULL
the	NULL
C-terminal	NULL
region	NULL
of	NULL
the	NULL
c-re/	NULL
protooncogene	NULL
contains	NULL
a	NULL
transcriptional	NULL
activation	NULL
domain	NULL
(	NULL
Bull	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
and	NULL
that	NULL
it	NULL
can	NULL
be	NULL
translocated	NULL
into	NULL
the	NULL
nucleus	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Ballard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
suggests	NULL
that	NULL
its	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
a	NULL
series	NULL
of	NULL
genes	NULL
described	NULL
as	NULL
responsive	NULL
to	NULL
NF-xB	NULL
alone	NULL
has	NULL
probably	NULL
been	NULL
overlooked	NULL
.	NULL

Constitutive	NULL
over-expression	NULL
of	NULL
the	NULL
ASP	NULL
protein	NULL
(	NULL
or	NULL
similar	NULL
deletion	NULL
mutants	NULL
)	NULL
is	NULL
expected	NULL
to	NULL
down-regulate	NULL
all	NULL
genes	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
member	NULL
of	NULL
the	NULL
rel/NF	NULL
xq	NULL
)	NULL
;	NULL
family	NULL
,	NULL
which	NULL
include	NULL
among	NULL
others	NULL
MHC	NULL
class	NULL
I	NULL
,	NULL
immunoglobulin	NULL
x-chain	NULL
,	NULL
the	NULL
IL-2	NULL
receptor	NULL
and	NULL
the	NULL
B-interferon	NULL
genes	NULL
.	NULL

It	NULL
could	NULL
thus	NULL
interfere	NULL
with	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
analyze	NULL
the	NULL
phenotype	NULL
of	NULL
transgenic	NULL
mice	NULL
over-expressing	NULL
ASP	NULL
.	NULL

Another	NULL
intriguing	NULL
issue	NULL
is	NULL
whether	NULL
there	NULL
exist	NULL
'natural	NULL
'	NULL
negative	NULL
transdominant	NULL
mutants	NULL
of	NULL
NF-xB	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
Id	NULL
member	NULL
of	NULL
the	NULL
helix-loop-helix	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
Benezra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
that	NULL
could	NULL
act	NULL
to	NULL
finely	NULL
tune	NULL
the	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
this	NULL
critical	NULL
factor	NULL
.	NULL

The	NULL
characterization	NULL
of	NULL
other	NULL
members	NULL
of	NULL
the	NULL
rel/NF-xB	NULL
family	NULL
should	NULL
help	NULL
to	NULL
answer	NULL
this	NULL
question	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Plasmids	NULL
The	NULL
v-re	NULL
!	NULL

l	NULL
cDNA	NULL
in	NULL
Bluescript	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
M.Hannink	NULL
and	NULL
H.Temin	NULL
(	NULL
Hannink	NULL
and	NULL
Temin	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

It	NULL
was	NULL
cut	NULL
at	NULL
the	NULL
HinclI	NULL
site	NULL
for	NULL
in	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
,	NULL
giving	NULL
rise	NULL
to	NULL
a	NULL
full-length	NULL
protein	NULL
.	NULL

The	NULL
c-re/	NULL
cDNA	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
N.Rice	NULL
(	NULL
Brownell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
and	NULL
was	NULL
cut	NULL
at	NULL
the	NULL
Xbal	NULL
site	NULL
in	NULL
the	NULL
polylinker	NULL
after	NULL
the	NULL
end	NULL
of	NULL
the	NULL
coding	NULL
region	NULL
.	NULL

Xba	NULL
,	NULL
Spe	NULL
and	NULL
ASP	NULL
plasmids	NULL
have	NULL
been	NULL
described	NULL
in	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
Taq	NULL
construct	NULL
(	NULL
see	NULL
Figure	NULL
1	NULL
)	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
Xba	NULL
construct	NULL
by	NULL
restriction	NULL
with	NULL
Tagl	NULL
,	NULL
filling-up	NULL
with	NULL
the	NULL
Klenow	NULL
enzyme	NULL
and	NULL
digestion	NULL
with	NULL
Xbal	NULL
.	NULL

The	NULL
resulting	NULL
fragment	NULL
(	NULL
amino	NULL
acids	NULL
287-502	NULL
)	NULL
was	NULL
ligated	NULL
between	NULL
the	NULL
Stul	NULL
(	NULL
amino	NULL
acid	NULL
10	NULL
)	NULL
and	NULL
Xbal	NULL
site	NULL
of	NULL
the	NULL
Xba	NULL
construct	NULL
.	NULL

This	NULL
construct	NULL
was	NULL
linearized	NULL
with	NULL
Xbal	NULL
for	NULL
in	NULL
vitro	NULL
transcription	NULL
.	NULL

The	NULL
NH	NULL
construct	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
mouse	NULL
precursor	NULL
of	NULL
p50	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
kindly	NULL
provided	NULL
by	NULL
S.Ghosh	NULL
and	NULL
D.Baltimore	NULL
)	NULL
by	NULL
digestion	NULL
with	NULL
NsiI	NULL
and	NULL
HindIII	NULL
(	NULL
this	NULL
fragment	NULL
codes	NULL
for	NULL
amino	NULL
acids	NULL
244-361	NULL
,	NULL
but	NULL
uses	NULL
as	NULL
a	NULL
start	NULL
codon	NULL
an	NULL
ATG	NULL
located	NULL
at	NULL
position	NULL
253	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
transdominant	NULL
negative	NULL
mutant	NULL
of	NULL
rel/NF-xB	NULL
This	NULL
fragment	NULL
was	NULL
then	NULL
cloned	NULL
between	NULL
the	NULL
PstI	NULL
and	NULL
HindIII	NULL
sites	NULL
of	NULL
pBluescript	NULL
KS+	NULL
,	NULL
and	NULL
linearized	NULL
with	NULL
Hind	NULL
for	NULL
in	NULL
vitro	NULL
transcription	NULL
.	NULL

The	NULL
expression	NULL
vectors	NULL
used	NULL
for	NULL
transient	NULL
transfections	NULL
into	NULL
mammalian	NULL
cells	NULL
were	NULL
constructed	NULL
as	NULL
follows	NULL
:	NULL
the	NULL
ASp	NULL
cDNA	NULL
was	NULL
excised	NULL
from	NULL
the	NULL
Bluescript	NULL
construct	NULL
by	NULL
digestion	NULL
with	NULL
HindIII	NULL
and	NULL
Xbal	NULL
and	NULL
subcloned	NULL
in	NULL
the	NULL
same	NULL
sites	NULL
of	NULL
the	NULL
Re-CMV	NULL
expression	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
,	NULL
to	NULL
give	NULL
CMV-ASP	NULL
.	NULL

The	NULL
Ltr-lue	NULL
plasmid	NULL
carries	NULL
the	NULL
reporter	NULL
luciferase	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
U3R	NULL
(	NULL
Bg/Il	NULL
-HindIH	NULL
fragment	NULL
)	NULL
of	NULL
HIV-1	NULL
(	NULL
LAVI	NULL
Bru	NULL
strain	NULL
)	NULL
LTR	NULL
.	NULL

The	NULL
3-Enh-TK-luc	NULL
construct	NULL
contains	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
synthetic	NULL
oligonucleotide	NULL
:	NULL
a	NULL
gett	NULL
ACAAGGGACTTTCCGCTGGGGACTTTCCAGGGa	NULL
a	NULL
TGTTCCCTGAAAGGCGACCCCTGAAAGGTCCCt	NULL
t	NULL
eg	NULL
a	NULL
corresponding	NULL
to	NULL
the	NULL
two	NULL
10	NULL
bp	NULL
repeats	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
-	NULL
107	NULL
to	NULL
-76	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
)	NULL
cloned	NULL
upstream	NULL
of	NULL
a	NULL
truncated	NULL
HSV	NULL
TK	NULL
promoter	NULL
(	NULL
-105	NULL
to	NULL
+51	NULL
)	NULL
in	NULL
a	NULL
TK-luc	NULL
expression	NULL
vector	NULL
(	NULL
Schwartz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Lower	NULL
case	NULL
letters	NULL
correspond	NULL
to	NULL
HindIII	NULL
compatible	NULL
linker	NULL
ends	NULL
that	NULL
do	NULL
not	NULL
belong	NULL
to	NULL
the	NULL
LTR	NULL
sequence	NULL
;	NULL
the	NULL
two	NULL
putative	NULL
NF-xB	NULL
binding	NULL
sites	NULL
are	NULL
in	NULL
bold	NULL
.	NULL

The	NULL
(	NULL
ab	NULL
}	NULL
4-CAT	NULL
construct	NULL
has	NULL
been	NULL
described	NULL
in	NULL
Isracl	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989b	NULL
)	NULL
and	NULL
contains	NULL
the	NULL
enhancer	NULL
element	NULL
of	NULL
the	NULL
H-2K	NULL
``	NULL
promoter	NULL
(	NULL
coordinates	NULL
-171	NULL
to	NULL
-	NULL
158	NULL
:	NULL
TGGGGATTCCCCAT	NULL
)	NULL
cloned	NULL
in	NULL
the	NULL
BamHI	NULL
site	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
conalbumin	NULL
transcription	NULL
start	NULL
site	NULL
in	NULL
the	NULL
conaCAT	NULL
expression	NULL
vector	NULL
(	NULL
Kimura	NULL
ef	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

The	NULL
(	NULL
393	NULL
)	NULL
H2-CAT	NULL
construct	NULL
contains	NULL
393	NULL
bp	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
H-2K	NULL
``	NULL
promoter	NULL
[	NULL
including	NULL
the	NULL
enhancer	NULL
element	NULL
of	NULL
the	NULL
(	NULL
ab	NULL
)	NULL
4-CAT	NULL
construct	NULL
]	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
and	NULL
has	NULL
been	NULL
described	NULL
in	NULL
Kimura	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Cell	NULL
cultures	NULL
and	NULL
reagents	NULL
The	NULL
CD4*	NULL
human	NULL
lymphoblastoid	NULL
T	NULL
cell	NULL
line	NULL
J.Jhan	NULL
derived	NULL
from	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
J.D.Fox	NULL
,	NULL
London	NULL
)	NULL
was	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
)	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
Boehringer	NULL
)	NULL
and	NULL
antibiotics	NULL
.	NULL

PMA	NULL
was	NULL
from	NULL
Sigma	NULL
(	NULL
St	NULL
Louis	NULL
)	NULL
.	NULL

Human	NULL
HeLa	NULL
and	NULL
monkey	NULL
Cos-7	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
new-born	NULL
calf	NULL
serum	NULL
.	NULL

Transfection	NULL
J.Jhan	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
DEAE	NULL
using	NULL
a	NULL
microtransfection	NULL
technique	NULL
(	NULL
Schwartz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
(	NULL
4	NULL
%	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
fixed	NULL
amount	NULL
(	NULL
30	NULL
ng	NULL
)	NULL
of	NULL
either	NULL
LTR-luc	NULL
or	NULL
3-Enh-TK-lue	NULL
.	NULL

CMV-ASP	NULL
was	NULL
co-transfected	NULL
with	NULL
either	NULL
plasmid	NULL
at	NULL
various	NULL
concentrations	NULL
(	NULL
30-200	NULL
ng	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
Re-CMV	NULL
was	NULL
used	NULL
at	NULL
the	NULL
same	NULL
concentrations	NULL
as	NULL
CMV-ASP	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
for	NULL
16	NULL
h	NULL
,	NULL
from	NULL
24	NULL
to	NULL
40	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
according	NULL
to	NULL
Schwartz	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

HeLa	NULL
and	NULL
Cos-7	NULL
cells	NULL
were	NULL
transfected	NULL
using	NULL
the	NULL
calcium	NULL
phosphate	NULL
co-precipitation	NULL
technique	NULL
as	NULL
described	NULL
in	NULL
Kimura	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

The	NULL
RSV-Sgal	NULL
construct	NULL
was	NULL
co-transfected	NULL
along	NULL
with	NULL
the	NULL
various	NULL
CAT	NULL
constructs	NULL
,	NULL
and	NULL
the	NULL
3-galactosidase	NULL
activity	NULL
was	NULL
used	NULL
to	NULL
correct	NULL
for	NULL
variations	NULL
due	NULL
to	NULL
variable	NULL
transfection	NULL
efficiencies	NULL
(	NULL
Kimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
4	NULL
ug	NULL
of	NULL
various	NULL
derivatives	NULL
of	NULL
the	NULL
p50	NULL
cDNA	NULL
cloned	NULL
in	NULL
pBluescript	NULL
were	NULL
linearized	NULL
with	NULL
appropriate	NULL
restriction	NULL
enzymes	NULL
and	NULL
in	NULL
vitro	NULL
transcribed	NULL
using	NULL
T7	NULL
or	NULL
T3	NULL
polymerase	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendation	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
,	NULL
ethanol	NULL
precipitated	NULL
and	NULL
redissolved	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
water	NULL
.	NULL

RNA	NULL
(	NULL
2	NULL
al	NULL
)	NULL
was	NULL
translated	NULL
in	NULL
wheat	NULL
germ	NULL
extracts	NULL
(	NULL
Promega	NULL
)	NULL
adjusted	NULL
to	NULL
60	NULL
mM	NULL
potassium	NULL
acetate	NULL
.	NULL

Immunoprecipitations	NULL
These	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
in	NULL
Murre	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
in	NULL
a	NULL
100	NULL
al	NULL
volume	NULL
containing	NULL
2	NULL
al	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
products	NULL
,	NULL
1	NULL
gl	NULL
of	NULL
anti-p50	NULL
antiserum	NULL
No	NULL
.	NULL

2	NULL
(	NULL
Kieran	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
anti-v-rel	NULL
(	NULL
Rice	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
or	NULL
anti-c-rel	NULL
(	NULL
Brownell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
and	NULL
20	NULL
al	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
CLAB	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-polyacrylamide	NULL
(	NULL
Laemmli	NULL
,	NULL
1970	NULL
)	NULL
using	NULL
10	NULL
or	NULL
12	NULL
%	NULL
Tricine-SDS	NULL
gels	NULL
(	NULL
Schigger	NULL
and	NULL
von	NULL
Jagow	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

Gel-shift	NULL
assays	NULL
These	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Israél	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

Glutaraldehyde	NULL
crosslinking	NULL
Equal	NULL
amounts	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
products	NULL
were	NULL
diluted	NULL
15	NULL
times	NULL
and	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
0.002	NULL
%	NULL
glutaraldehyde	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
immunoprecipitated	NULL
with	NULL
anti-p50	NULL
antiserum	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
500	NULL
ul	NULL
and	NULL
analyzed	NULL
on	NULL
12	NULL
%	NULL
polyacrylamide-SDS-Tricine	NULL
gels	NULL
.	NULL

1831	NULL
F.Logeat	NULL
et	NULL
al	NULL
.	NULL

Acknowledgements	NULL
We	NULL
thank	NULL
N.	NULL
Rice	NULL
for	NULL
kindly	NULL
providing	NULL
anti-v-rel	NULL
and	NULL
anti-c-rel	NULL
antisera	NULL
,	NULL
and	NULL
M.Hannink	NULL
and	NULL
H.M.Temin	NULL
for	NULL
the	NULL
rel	NULL
expression	NULL
vectors	NULL
.	NULL

V.B	NULL
.	NULL

is	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Association	NULL
pour	NULL
le	NULL
Développement	NULL
de	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
and	NULL
R.T.	NULL
is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
'poste	NULL
vert	NULL
'	NULL
from	NULL
the	NULL
Institut	NULL
National	NULL
pour	NULL
la	NULL
Santé	NULL
et	NULL
la	NULL
Recherche	NULL
Médicale	NULL
.	NULL

References	NULL
Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
,	NULL
242	NULL
,	NULL
540-546	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
3	NULL
,	NULL
1689-1699	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
and	NULL
Sharp	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
7	NULL
,	NULL
305-313	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
and	NULL
Sharp	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
723-727	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
,	NULL
Leclair.K.P	NULL
.	NULL

,	NULL
Singh	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Sharp	NULL
,	NULL
P	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
1406-1414	NULL
.	NULL

Ballard	NULL
,	NULL
D	NULL
.	NULL

W.	NULL
,	NULL
Walker	NULL
,	NULL
W.H	NULL
.	NULL

,	NULL
Doerre	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Sista	NULL
,	NULL
P.	NULL
,	NULL
Molitor	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Dixon	NULL
,	NULL
E.P	NULL
.	NULL

,	NULL
Peffer	NULL
,	NULL
N.J.	NULL
,	NULL
Hannink	NULL
,	NULL
M.	NULL
and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
63	NULL
,	NULL
803-814	NULL
.	NULL

Benezra	NULL
,	NULL
R.	NULL
,	NULL
Davis	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
Lockshon	NULL
,	NULL
D.	NULL
,	NULL
Turner	NULL
,	NULL
D.L	NULL
.	NULL

and	NULL
Weintraub	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
61	NULL
,	NULL
49-59	NULL
.	NULL

Brownell	NULL
,	NULL
E.	NULL
,	NULL
Mittereder	NULL
,	NULL
N	NULL
.	NULL

and	NULL
Rice	NULL
,	NULL
N.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Oncogene	NULL
,	NULL
4	NULL
,	NULL
934-942	NULL
.	NULL

Bull	NULL
,	NULL
P.	NULL
,	NULL
Morley	NULL
,	NULL
K.L	NULL
.	NULL

,	NULL
Hoekstra	NULL
,	NULL
M.F	NULL
.	NULL

,	NULL
Hunter	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Verma	NULL
,	NULL
I	NULL
.	NULL

M.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
5473-5485	NULL
.	NULL

Burke	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
Hirschfeld	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Shirayoshi	NULL
,	NULL
Y.	NULL
,	NULL
Kasik	NULL
,	NULL
J.W	NULL
.	NULL

,	NULL
Hamada	NULL
,	NULL
K.	NULL
,	NULL
Appella	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Ozato	NULL
,	NULL
K	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
169	NULL
,	NULL
1309-1321	NULL
.	NULL

Fan	NULL
,	NULL
C.M	NULL
.	NULL

and	NULL
Maniatis	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
4	NULL
,	NULL
29-42	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Gifford	NULL
,	NULL
A.M.	NULL
,	NULL
Riviere	NULL
,	NULL
L.R	NULL
.	NULL

,	NULL
Tempst.P	NULL
.	NULL

,	NULL
Nolan	NULL
,	NULL
G.P	NULL
.	NULL

and	NULL
Baitimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
1019-1029	NULL
.	NULL

Gilmore	NULL
,	NULL
T.D	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
841-843	NULL
.	NULL

Glass	NULL
,	NULL
C.K	NULL
.	NULL

,	NULL
Lipkin	NULL
,	NULL
S	NULL
.	NULL

M.	NULL
,	NULL
Devary,0	NULL
.	NULL

V.	NULL
and	NULL
Rosenfeld	NULL
,	NULL
M.G	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Cell	NULL
,	NULL
59	NULL
,	NULL
697-708	NULL
.	NULL

Hannink	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Temin	NULL
,	NULL
H.M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
4323-4336	NULL
.	NULL

Herskowitz	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
329	NULL
,	NULL
219-222	NULL
.	NULL

Ip	NULL
,	NULL
Y.T	NULL
.	NULL

,	NULL
Kraut	NULL
,	NULL
R.	NULL
,	NULL
Levin	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Rushlow	NULL
,	NULL
C	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
,	NULL
64	NULL
,	NULL
439-446	NULL
.	NULL

Israél	NULL
,	NULL
A.	NULL
,	NULL
Kimura	NULL
,	NULL
A.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Yano	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Kanellopoulos	NULL
,	NULL
J.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O	NULL
.	NULL

and	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
2653-2657	NULL
.	NULL

Israél	NULL
,	NULL
A.	NULL
,	NULL
Yano	NULL
,	NULL
S.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
and	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

(	NULL
19892	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
17	NULL
,	NULL
5245-5257	NULL
.	NULL

Israél	NULL
,	NULL
A.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Hatat	NULL
,	NULL
.D	NULL
.	NULL

,	NULL
Piette	NULL
,	NULL
J.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Wallach	NULL
,	NULL
D.	NULL
,	NULL
Fellous	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1989b	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
3793-3800	NULL
.	NULL

Jones	NULL
,	NULL
N	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
61	NULL
,	NULL
9-11	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Vandekerckhove	NULL
,	NULL
J.	NULL
,	NULL
Lottspeich	NULL
,	NULL
F.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Urban	NULL
,	NULL
M.B	NULL
.	NULL

,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Bacuerie	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
1007-1018	NULL
.	NULL

Kimura	NULL
,	NULL
A.	NULL
,	NULL
Isracl	NULL
,	NULL
A.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O	NULL
.	NULL

and	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cell	NULL
,	NULL
44	NULL
,	NULL
261-272	NULL
.	NULL

Laemmli	NULL
,	NULL
U.K.	NULL
(	NULL
1970	NULL
)	NULL
Nature	NULL
,	NULL
227	NULL
,	NULL
680-685	NULL
.	NULL

Mitchell	NULL
,	NULL
P.J	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
245	NULL
,	NULL
371-378	NULL
.	NULL

Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Walker	NULL
,	NULL
W.H	NULL
.	NULL

,	NULL
Doerre	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Ballard	NULL
,	NULL
D.W	NULL
.	NULL

and	NULL
Green	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
$	NULL
7	NULL
,	NULL
10028-10032	NULL
.	NULL

Murre	NULL
,	NULL
C.	NULL
,	NULL
McCaw	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Vaessin	NULL
,	NULL
H.	NULL
,	NULL
Caudy	NULL
,	NULL
M.	NULL
,	NULL
Jan	NULL
,	NULL
L.Y	NULL
.	NULL

,	NULL
Jan	NULL
,	NULL
Y.N	NULL
.	NULL

,	NULL
Cabrera	NULL
,	NULL
C.V.	NULL
,	NULL
Buskin	NULL
,	NULL
J.N	NULL
.	NULL

,	NULL
Haushkan	NULL
,	NULL
$	NULL
.D	NULL
.	NULL

,	NULL
Lassar	NULL
,	NULL
A.B	NULL
.	NULL

,	NULL
Weintraub	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Cell	NULL
,	NULL
58	NULL
,	NULL
537-544	NULL
.	NULL

Nabel	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
326	NULL
,	NULL
711-713	NULL
.	NULL

Rice	NULL
,	NULL
N.R	NULL
.	NULL

,	NULL
Copeland	NULL
,	NULL
Simek	NULL
,	NULL
S.	NULL
,	NULL
Orozzlan	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Gilden	NULL
,	NULL
R.V	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Virology	NULL
,	NULL
149	NULL
,	NULL
217-229	NULL
.	NULL

Schiigger	NULL
,	NULL
H	NULL
.	NULL

and	NULL
von	NULL
Jagow	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
166	NULL
,	NULL
369-378	NULL
.	NULL

Schwartz,0	NULL
.	NULL

,	NULL
Virelizier	NULL
,	NULL
J.-L.	NULL
,	NULL
Montagnier	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Hazan	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Gene	NULL
,	NULL
88	NULL
,	NULL
197-205	NULL
.	NULL

Sen	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cell	NULL
,	NULL
47	NULL
,	NULL
921-928	NULL
.	NULL

Turner	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
243	NULL
,	NULL
1689-1694	NULL
.	NULL

Yano,0	NULL
.	NULL

,	NULL
Kanellopoulos	NULL
,	NULL
J.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
6	NULL
,	NULL
3317-3324	NULL
.	NULL

Received	NULL
on	NULL
December	NULL
21	NULL
,	NULL
1990	NULL
;	NULL
revised	NULL
on	NULL
February	NULL
25	NULL
,	NULL
1991	NULL
1832	NULL

